Advertisement
Advertisement

AEMD

AEMD logo

AETHLON MEDICAL INC

3.08
USD
Sponsored
-0.07
-2.22%
Aug 10, 16:00 UTC -4
Closed
exchange

After-Market

3.19

+0.11
+3.73%

AETHLON MEDICAL INC Profile

About

Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.

Info & Links

CEO

James B. Frakes

Headquarters

11555 SORRENTO VALLEY ROAD, SUITE 203
SAN DIEGO, CA 92121, UNITED STATES

Industry

Medical Hmos

Sector

Medical

Website

http://www.aethlonmedical.com

Auditor

HASKELL & WHITE LLP

Share holders

55

Employees

9

AETHLON MEDICAL INC Statistics

Valuation Measures

Market Capitalization2

1.68M

Enterprise Value

-3.34M

Enterprise Value/EBITDA(ttm)

0.48

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.20

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-137.73%

Return on Invested Capital(ttm)

-145.97%

Return on Assets(ttm)

-105.87%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-6.97M

Net Income Available to Common(ttm)

-7.15M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

1.41

52-Week Change

-94.99%

S&P 500 52-Week Change

21.65%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

474.11K

Dividend Yield

0.00%

Float4

645.00K

% Held by Insiders

0.71%

% Held by Institutions

1.99%

Balance Sheet

Total Cash(mrq)

5.03M

Total Cash Per Share(mrq)

10.60

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.85%

Quick Ratio(mrq)

3.85%

Book Value Per Share(mrq)

15.56

Cash Flow

Operating Cash Flow Per Share(ytd)

-51.92

Free Cash Flow(ytd)

-7.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement